NEW YORK (GenomeWeb News) – Dalton Pharma Services will use Thermo Fisher Scientific’s enzyme-based technology to make nucleic acid biopolymers for use in drug development research projects, Toronto-base Dalton said today.
 
Dalton will produce poly-inosine and poly-cytosine in accordance with current good manufacturing practice regulations.
 
These polynucleotides are used as catalysts to stimulate immune responses when they are combined with other substances in a drug, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.